Kaitlyn D’Onofrio

DocwireNews

The addition of aprepitant to a regimen to reduce chemotherapy-induced nausea among women was effective in a recent phase 3, double-blind, placebo-controlled randomized clinical trial.
Women aged ≤50 years with gastrointestinal <a href="https://www.docwirenews.com/cardiology/tofacitinib-review-heart-issues-cancer-canada-fda/">cancer</a> who had little to no history of alcohol use (defined as alcohol intake of &lt;5 times per week and 100 g per day) who were receiving FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens were included in the trial. They were randomized to one of two groups: the aprepitant group (aprepitant, 125 mg, orally 60 minutes before initiation of chemotherapy on day one and 80 mg orally each morning of days two and three; palonosetron, 0.25 mg, intravenously; and dexamethasone, 6 mg, orally 30 minutes before chemotherapy initiation on day one) or the placebo group (placebo, 125 mg, orally 60 minutes before initiation of chemotherapy on day one and 80 mg orally on each morning of days two and three; palonosetron, 0.25 mg, intravenously; and dexamethasone, 12 mg, orally 30 minutes before chemotherapy initiation on day one).
The study spanned four clinical centers in China. The complete response (CR) rate, the main outcome, was defined as the rate of patients   without emesis episodes or rescue medication use during the overall phase of the first cycle. Secondary and exploratory outcomes included incidences of vomiting and nausea.
Of 248 patients enrolled in the trial, 243 were evaluated in the final analysis: 125 who received aprepitant and 118 who received placebo. The mean age of the entire cohort was 40.1 years.
Overall, patients in the aprepitant group were much more likely than women who received placebo to achieve CR (87% vs 66.7%; P&lt;0.001). This was also true when stratified by different trial phases (acute: 92.7% vs 75.8%, respectively; P=0.001; delayed: 88.6% vs 70%, respectively; P=0.001). Adverse events (AEs) rates were comparable between the groups (80% vs 81.3%, respectively; P=0.79). The aprepitant group had no grade 3 or 4 treatment-related AEs.
The study was published in <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2778342">JAMA Network Open</a>.

Andrew Moreno

Genetic Classification Model Differentiates MDS Stem, Progenitor Cells from Healthy Bone Marrow

ASH 2024

Cecilia Brown

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line Treatment of ES-SCLC

Small Cell Lung Cancer

Genetic Study Uncovers Potential Therapy-Actionable Transcription Factors in MDS

Latest News

Aprepitant Effective in Reducing Nausea from Chemo in Women

GI Cancer

The addition of aprepitant to a regimen to reduce chemotherapy-induced nausea among women was effective in a recent phase 3, double-blind, placebo-controlled randomized ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe